Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$148.98 USD
-3.69 (-2.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$148.98 USD
-3.69 (-2.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Zacks News
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -6.63% and 22.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
What Awaits Selecta Biosciences (SELB) This Earnings Season?
by Zacks Equity Research
In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.
Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More
by Kinjel Shah
Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.
Will Sarepta Therapeutics (SRPT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Sarepta Completes Rolling NDA Submission for New DMD Therapy
by Zacks Equity Research
Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.
Sarepta Inks Agreement With Codiak to Develop Gene Therapies
by Zacks Equity Research
Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SRPT) Outperforming Other Medical Stocks This Year?
Regeneron (REGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Regeneron (REGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sarepta's Gene Therapy Promising in Muscular Dystrophy Study
by Zacks Equity Research
Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.
Sarepta Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sarepta Therapeutics.
Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do You Always Look for Earnings Beat? 5 Sectors to Play
by Sanghamitra Saha
These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.
Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRPT) Outperforming Other Medical Stocks This Year?
Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.
Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy
by Zacks Equity Research
Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year.
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 89.96% and 0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy
5 Stocks to Win Big This Brutal Q1 Earnings Season
by Tirthankar Chakraborty
There are certain sectors whose earnings are expected to perk up in the first quarter despite this pandemic. Such sectors include Construction, Medical, Consumer Staples and Utilities.
Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.